

- 1 -

MODIFIED PICTET-SPENGLER REACTION
AND PRODUCTS PREPARED THEREFROM

FIELD OF THE INVENTION

The present invention relates to a modified Pictet-Spengler reaction for introducing a second stereogenic center into a compound. More particularly, the present invention relates to a modified Pictet-Spengler reaction that provides a desired cis- or trans-diastereomer of a polycyclic compound having two stereogenic centers, in high yield and high purity.

BACKGROUND OF THE INVENTION

Compounds that exhibit biological activity typically contain at least one asymmetric carbon atom, i.e., at least one chiral center. A particular stereoisomer of such a compound usually exhibits excellent biological activity, whereas the other stereoisomers exhibit no or little biological activity. Accordingly, investigators strive to synthesize the biologically active stereoisomer, while minimizing or eliminating synthesis of the inactive or less active stereoisomer.

Stereochemical purity is important in the pharmaceutical field, where many of the most often prescribed drugs exhibit chirality. For example, the L-enantiomer of the β -adrenergic blocking agent, propranolol, is known to be 100 times more potent than its D-enantiomer. Additionally, optical purity is important in the pharmaceutical field because

- 2 -

certain stereoisomers impart a deleterious effect, rather than an advantageous or inert effect. For example, it is believed that the D-enantiomer of thalidomide is a safe and effective sedative when 5 prescribed for the control of morning sickness during pregnancy, whereas its corresponding L-enantiomer is believed to be a potent teratogen.

A stereoselective synthesis, therefore, permits the preparation of a more useful drug product. For example, the administered dose of a drug 10 can be reduced because only the active stereoisomer is administered to an individual, as opposed to a mixture which contains a large amount of inactive stereoisomer. This reduced dose of active stereoisomer also reduces adverse side effects compared to 15 a dose containing a mixture of stereoisomers. In addition, a stereoselective synthesis is more economical because a step of separating the desired stereoisomer from the undesired stereoisomer is simplified or eliminated, and raw material wastes 20 and costs are decreased because reactants are not consumed in the synthesis of undesired stereoisomers.

Many biologically active compounds contain 25 two asymmetric carbon atoms, i.e., two stereogenic centers, wherein each asymmetric carbon atom is a member of a ring system and each is bonded to a hydrogen atom and to a substituent different from a hydrogen atom. The nonhydrogen substituents of the 30 asymmetric carbon atoms therefore can be in a cis or a trans configuration. A particularly difficult


- 3 -

problem encountered in the synthesis of such biologically active compounds is the high yield and high purity preparation of a particular stereoisomer, i.e., the desired diastereomer, wherein the 5 nonhydrogen substituents of the asymmetric carbon atoms are in the *cis* configuration, or the *trans* configuration, depending upon which diastereomer is the more biologically active.

For such compounds, it is necessary to 10 provide a synthetic pathway that provides each stereogenic center of correct stereochemistry, and thereby yield the desired diastereomer. The synthetic pathway also should provide a high yield of the desired diastereomer in as few steps as 15 possible, with a minimum of diastereomer separation and purification.

For example, U.S. Patent No. 5,859,006, incorporated herein by reference, discloses the synthesis of (6*R*,12*aR*)-2,3,6,7,12,12*a*-hexahydro-2-20 methyl-6-(3,4-methylenedioxyphenyl)-pyrazino-[2',1':6,1]pyrido[3,4-*b*]indole-1,4-dione having a structure (I):

- 4 -



(I)

5

Compound (I) has two asymmetric carbon atoms, each denoted by an asterisk, wherein the nonhydrogen substituents of the asymmetric carbon atoms are in the *cis* configuration. Compound 10 (I) can be prepared by the two synthetic pathways disclosed in U.S. Patent No. 5,859,006. Compound (I) is a potent and selective inhibitor 15 of the phosphodiesterase enzyme PDE5, and has various therapeutic uses, for example, the treatment of male erectile dysfunction.


The first synthetic pathway (A), from D-tryptophan, has few steps, but the yield of the desired diastereomer (i.e., Compound II) is poor and requires a separation step from the trans-stereoisomer (Compound IIa). Pathway (A) also utilizes the highly corrosive trifluoroacetic acid (i.e., TFA or CF₃CO₂H). The key step in pathway A is a classic 20 Pictet-Spengler reaction using D-tryptophan methyl ester and piperonal to yield substituted tetrahydro-β-carboline Compounds (II) and (IIa). The second 25

- 5 -

pathway (B) provides a better yield of the desired Compound I, but requires numerous synthetic steps. In each synthetic pathway, the key intermediate in the synthesis of Compound (I) is Compound (II).

5 Compound (I) then is synthesized from Compound (II) in two straightforward synthetic steps.


Pathway A



D-Tryptophan
methyl ester

Piperonal

10




Compound (II)
(cis-isomer) (42% yield)
(desired)

Compound (IIa)
(trans-isomer) (28% yield)
(undesired)


15

- 6 -


Pathway B






5



10




- 7 -




10

- 8 -

Pathway from Compound (II) to Compound (I)



5



10

The overall yield of Compound (I) using synthetic pathway (A) or (B) is about 25% to about 30%.



Pathway (B) requires several synthetic steps, and, therefore, was considered inconvenient. A key step in the synthesis of Compound (I) is the preparation of Compound (II) in the shorter synthetic pathway (A). The preparation of Compound (II) in pathway (A) utilizes a Pictet-Spengler cyclization between D-tryptophan methyl ester and piperonal in dichloromethane (CH_2Cl_2) with two equivalents of trifluoroacetic acid at 4°C which

- 9 -

provides, after five days, a mixture of two diastereoisomers, i.e., the desired *cis*-isomer tetrahydro- β -carboline Compound (II) ((1*R*,3*R*)) and the undesired *trans*-isomer tetrahydro- β -carboline Compound (IIa) ((1*S*,3*R*)) in a ratio of about 60/40. From this mixture, the pure *cis*-isomer (i.e., Compound (II)) can be obtained by fractional crystallization in a 42% yield (ee>99% (chiral HPLC)).

The Pictet-Spengler reaction is a direct method of providing the tetrahydro- β -carboline ring system that is present in Compound (I). In general, the Pictet-Spengler reaction utilizes a tryptophan ester and an aldehyde to yield a mixture of the *cis*-1,3- and *trans*-1,3-tetrahydro- β -carbolines illustrated below. R^2 typically is C_{1-4} alkyl and R^1 can be aliphatic or aromatic, for example, see U.S. Patent Nos. 5,859,006 and 5,981,527, each incorporated herein by reference.

20



- 10 -

It would be an important advance in the art to provide a modified Pictet-Spengler cyclization reaction that substantially improves the diastereoselectivity of the reaction. In particular,
5 it would be an advance in the art to improve pathway A, which utilizes the Pictet-Spengler reaction between commercially available D-tryptophan methyl ester and piperonal, or other aliphatic or aromatic aldehyde, in a straightforward method to prepare
10 enantiomerically pure Compound (II), or similar tetrahydro- β -carboline, and that overcomes the disadvantages of the classic Pictet-Spengler reaction, such as use of TFA, long reaction times, and difficult product separations.

15

SUMMARY OF THE INVENTION

The present invention is directed to a method of preparing a desired diastereomer, i.e., cis or trans, of a polycyclic compound having two asymmetric ring carbon atoms. More particularly,
- 20 the present invention is directed to a method of preparing a desired diastereomer of a tetrahydro- β -carboline compound having two asymmetric carbon atoms utilizing a modified Pictet-Spengler reaction.

Prior investigators attempted to prepare a
25 desired diastereomer of a polycyclic ring system containing two asymmetric ring carbon atoms by performing a Pictet-Spengler cyclization reaction. These attempts generally were limited in success because the reaction was performed in a corrosive medium, led to mixtures of diastereomers that ad-

- 11 -

versely affected reaction yield, and required several days to perform. The present method provides the desired diastereomer in good yield and short reaction times, and avoids the use of TFA.

5 More particularly, the present invention is directed to a method of preparing a desired diastereomer of a tetrahydro- β -carboline compound having two asymmetric carbons utilizing a modified Pictet-Spengler cyclization reaction wherein the
10 reaction is performed using a solvent in which only one of the diastereomers is soluble. In preferred embodiments, the desired diastereomer is insoluble in the solvent, and undesired diastereomer is soluble.

15 Another aspect of the present invention is to increase the yield of the desired diastereomer by allowing the undesired diastereomer to equilibrate in solution to provide additional desired diastereomer that precipitates from solution, and thereby increase the yield of the desired diastereomer at the expense of the undesired diastereomer.
20

25 These and other aspects and novel features of the present invention will become apparent from the following detailed description of the preferred embodiments.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is directed to a method of preparing a desired diastereomer of a polycyclic compound having two asymmetric carbon atoms as members of a ring system. The method
30

- 12 -

utilizes an improved Pictet-Spengler reaction that provides a desired tetrahydro- β -carboline diastereomer in high yield, high purity, and in a short process time. The improved Pictet-Spengler reaction 5 also avoids the use of TFA in the reaction.

Although the synthesis of Compounds (I) and (II) are particularly discussed herein, the present method is not limited to these compounds. The present method also can be used to synthesize 10 the desired diastereomer of other tetrahydro- β -carbolines by a judicious selection of starting tryptophan ester, e.g., the D- or L-form, the starting aldehyde, and the reaction solvents utilized in the present modified Pictet-Spengler cyclization reaction. 15

Typically, the Pictet-Spengler reaction proceeds through generation of an imine under neutral conditions, then effecting cyclization using trifluoroacetic acid (TFA) in dichloromethane 20 (CH_2Cl_2) at a low temperature (4°C). In addition to starting with an imine, N-substitution of the tryptophan amino ($-\text{NH}_2$) group often is used to provide a cis-diastereomer. The Pictet-Spengler reaction disclosed in U.S. Patent No. 5,859,006 uses such conditions. As discussed above, the standard Pictet-Spengler reaction has the disadvantages of a long 25 cycle time, a low yield of the desired cis-diastereomer, and use of the corrosive TFA.

The present invention overcomes problems 30 associated with the classic Pictet-Spengler reaction, e.g., improves the yield and purity of the

- 13 -

desired diastereomer, and utilizes a more facile synthetic route. In particular, the present invention is directed to a simplified Pictet-Spengler reaction for generating a second ring stereogenic center, wherein the desired *cis*- or *trans*-diastereomer can be prepared in high yield and purity by performing the reaction in a solvent in which the desired disastereomer is insoluble and the undesired diastereomer is soluble. The modified Pictet-Spengler reaction of the present invention also utilizes an N-unsubstituted starting material, e.g., tryptophan, as the hydrochloride salt, and eliminates the use of TFA. The elimination of TFA from the reaction has substantial advantages, including improved isolation/identification of the tryptophan methyl hydrochloride and overcoming the corrosive properties of TFA.

The selection of a proper solvent for use in the present modified Pictet-Spengler reaction is well within the skill of persons in the art. For example, in the preparation of Compound (II) by the Pictet-Spengler cyclization reaction, isopropyl alcohol was found to solubilize the undesired *trans*-diastereomer, whereas the desired *cis*-diastereomer precipitated from the reaction mixture. In addition, the solubilized *trans*-diastereomer is in dynamic equilibrium with the desired *cis*-diastereomer. Accordingly, as the *cis*-diastereomer Compound (II) is formed in solution and immediately precipitates, its concentration is lowered relative to the remaining *trans*-diastereomer Compound (IIa),

- 14 -


thereby providing a concentration differential that forces the equilibrium to provide additional cis-diastereomer. This continuous driving of the reaction increases both the yield and purity of the
5 desired cis-diastereomer.

In particular, the present invention utilizes a modified Pictet-Spengler cyclization reaction to form a tetrahydro- β -carboline ring system having two stereogenic centers. The reaction is
10 performed in a solvent wherein the desired diastereomer is soluble at reflux temperature or below, and the undesired diastereomer is insoluble at reflux temperature or below. This solubility difference allows a fast and easy separation of the desired
15 diastereomer from the undesired diastereomer. Furthermore, the dynamic cis-trans equilibrium in solution allows a more complete conversion of the starting materials to the desired diastereomer, and a more complete separation of the desired diastereomer from the undesired diastereomer.
20 Accordingly, another advantage of the present invention is a decrease in costs attributed to a more efficient use
of reagents.

As previously stated, the selection of a
25 reaction solvent having the requisite solubility properties is within the ability of a person skilled in the art. The selection merely requires determination of the solubility of each diastereomer in a particular solvent, and a solvent selection that
30 meets the above-described solubility/insolubility parameters for the two diastereomers.

- 15 -


The following is a nonlimiting example of the present invention, illustrating the synthesis of Compound (II) by the modified Pictet-Spengler reaction (Step 2), and the subsequent synthesis of Compound (I) from Compound (II) (Steps 3 and 4).



Step 1
Monitored by HPLC

- i) MeOH under N₂
- ii) SOCl₂ (reflux)
- iii) distill, cool
- iv) MTBE, filter (92% yield)


10



Step 2
Monitored by HPLC

- i) i-PrOH under N₂
- ii) piperonal (reflux)
- iii) cool, filter (93% yield)

15




Compound (II)

Step 3
Monitored by HPLC


- i) THF/H₂O under N₂
- ii) Et₃N
- iii) ClCH₂C(O)Cl
- iv) i-PrOH/H₂O, filter (95% yield)

- 16 -



Step 4
Monitored by HPLC

- i) THF under N₂
- ii) MeNH₂ (40% aq)
- iii) aqueous HCl
- iv) i-PrOH/H₂O, filter
(95% yield)



Compound (I)

5

In general, the synthesis of compound (I)
 10 using the method of the present invention involves a four-step synthetic pathway. The first step is an esterification in methanol (MeOH) using thionyl chloride (SOCl₂) under reflux. The product is crystallized and isolated by filtration. The second
 15 step involves the present novel and simplified variation of the Pictet-Spengler reaction, wherein D-tryptophan methyl ester hydrochloride is admixed with piperonal in isopropyl alcohol (i-PrOH) and heated under reflux to form a mixture of diaster-

- 17 -

eomeric adducts. Because the desired *cis*-diastereomer (Compound (II)) is substantially insoluble in isopropyl alcohol at reflux temperature and below, the *cis*-diastereomer crystallizes from solution 5 leaving a dynamic *cis-trans* equilibrium in solution. As the *cis*-diastereomer precipitates from the isopropyl alcohol, the equilibrium is driven towards the *cis*-diastereomer until the concentration of the *cis*-diastereomer is sufficiently low to remain in 10 solution. The desired diastereomer is isolated in greater than 90% yield by crystallization and filtration.

The third step involves an aqueous tetrahydrofuran (THF) acylation of the amino (NH_2) moiety 15 of Compound (II), followed by crystallization and filtration. Ring closure with methylamine (MeNH_2) completes the ring-forming sequence. After solvent exchange, the product is crystallized from aqueous isopropyl alcohol or other suitable solvent, and 20 filtration provides Compound (I) in an overall yield of about 77%.


In general, the present modified Pictet-Spengler reaction can be used to prepare the desired diastereomer of tetrahydro- β -carboline-based compounds without limitation. For example, the present modified Pictet-Spengler reaction can be used to 25 synthesize the desired diastereomer of classes of compounds disclosed in U.S. Patent Nos. 5,859,006; 5,981,527; 6,001,847, WO 02/28859, WO 02/28865, 30 WO 02/10166, WO 02/36593, WO 01/94345, WO 02/00658, WO 02/00657, WO 02/38563, WO 01/94347, WO 02/94345,

- 18 -

WO 02/00656, PCT/US01/49393, PCT/US02/13719,
PCT/US02/00017, PCT/US02/10367, PCT/US02/13703,
PCT/US02/11791, and PCT/US02/13897, each incorpo-
rated herein by reference, and other substituted
5 tetrahydro- β -carbolines.

In addition to the preparation of tetra-
hydro- β -carboline diketo-piperazines, like Compound
(I), the present method can be used to prepare
tetrahydro- β -carboline hydantoins (III) of desired
10 stereochemistry by reacting a compound such as
Compound (II) with an isocyanate having a formula
 R^4NCO , wherein R^4 is aliphatic or aromatic. See U.S.
Patent No. 6,001,847, incorporated herein by refer-
ence.

15




(III)

The following provides a detailed exem-
20 plary preparation of Compound (I) utilizing the
method of the present invention.

- 19 -


Step 1



Monitored by HPLC

- i) MeOH under N₂
- ii) SOCl₂ (reflux)
- iii) distill, cool
- iv) MTBE, filter (92% yield)

5



10 D-Tryptophan (50.0 kg, 245 mol) was suspended in MeOH (270 L), then added to a prepared solution of SOCl₂ (67.0 kg, 563 mol) in MeOH (250 L) at ambient temperature under a nitrogen (N₂) atmosphere. The resulting solution was stirred at reflux for 1 to 2 hours, then MeOH was distilled from the reaction mixture to about 50% of original volume. Methyl t-butyl ether (MTBE) (350 L) was added, and the solution was cooled to 0° to 5°C, with continued stirring for 1 hour. The product was filtered, washed with cold MTBE (150 L), and dried in vacuum at 60°C to yield 57.6 kg (92.4%) of D-tryptophan methyl ester hydrochloride. ¹H NMR (400 MHz DMSO) δ: 11.15 (1H, s), 8.70 (2H, exch.), 7.50 (1H, d, J=8.2 Hz), 7.35 (1H, d, J=8.2 Hz), 7.24 (1H, s), 7.08-7.05 (1H, m), 7.00-6.97 (1H, m), 4.18-4.16 (1H, m), 3.61 (3H, s), 3.36-3.25 (2H, m). HPLC

15


20

25

- 20 -

Details: Column: SB-Phenyl 4.6 x 250 mm; Eluent: Isocratic 80% ($H_2O+0.1\%$ TFA) / 20% ACN (acetonitrile); Temperature: 40°C; Flow Rate = 1 mL/min; UV Detection = 285 nm; Injection Volume = 20 μL ; Diluent = 5 1:1 ACN/ H_2O ; and Retention Time = 10.0 min.


Step 2



Monitored by HPLC

- i) $i\text{-PrOH}$ under N_2
- ii) piperonal (reflux)
- iii) cool, filter (93% yield)

10



15

(Compound II)

D-Tryptophan methyl ester hydrochloride
20 (50.0 kg, 196 mol) was suspended in isopropyl alcohol (500 L) and treated with piperonal (32.4 kg, 216 mol) at ambient temperature under an N_2 atmosphere. The mixture was stirred between 70°C and reflux (82°C) for 16 to 18 hours. At this time, the 25 reaction mixture contained less than 3% Compound

- 21 -

IIa. The reaction mixture then was cooled to 0°C, filtered, and washed with cold isopropyl alcohol (150 L). The product was dried under vacuum at less than 60°C to yield 69.8 kg (92%) of *cis*-1-(1,3-5 benzodioxol-5-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester (Compound II)). ^1H NMR (400 MHz DMSO) δ : 10.81 (1H, s), 10.67 (1H, exch.), 10.21 (1H, exch.), 7.52 (1H, d, J=8.0 Hz), 7.27 (1H, d, J=8.0 Hz), 7.11 (1H, m), 7.05-6.95 (4H, m), 6.08 (2H, s); 5.85 (1H, m), 4.71 (1H, m), 3.82 (3H, s), 3.39-3.23 (2H, m). HPLC Details: Column: SB-Phenyl 4.6 x 250 mm; ACN/(H₂O+0.1% TFA) gradient; Temperature: 40°C; Flow Rate = 1 mL/min; UV Det. = 285 nm; Injection Volume = 20 μ L; Diluent = 1:1 ACN/H₂O; Sample concentration: about 0.1 mg/mL; and Retention time = 6.0 min.

In a preferred method of preparing Compound (II) by the present method, a small seed amount of Compound (II), i.e., about 0.05% to about 20 1%, and preferably about 0.05% to about 0.25%, based on the weight of D-tryptophan methyl ester hydrochloride, is added to the reaction mixture prior to heating. This seed amount induces crystallization 25 of the *cis*-carboline Compound (II) in the reaction mixture.

When isopropyl alcohol is used as the solvent, it is preferred that the alcohol is anhydrous, e.g., 0.1% water or less, by weight, because appreciable amounts of water can adversely affect the 30 rate of reaction. It is especially preferred that the isopropyl alcohol is essentially free of

- 22 -


acetone, i.e., contains 0.3% acetone or less, by weight, to avoid formation of an undesired by-product.

Use of a higher boiling solvent (e.g., n-
5 propanol, toluene, dimethylformamide, acetonitrile, or acetic acid) leads to faster reaction times with comparable product yield and purity.

Other solvents useful in the preparation
of Compound (II) using a Pictet-Spengler reaction
10 (Step 2) of the present invention include, but are
not limited to, aromatic solvents (e.g., toluene, benzene, or xylene), a nitrile (e.g., acetonitrile or propionitrile), an ester (e.g., ethyl acetate), an alcohol (e.g., a propanol or butanol), an ether
15 (e.g., THF, MTBE, or dioxane), an aliphatic hydrocarbon (e.g., hexane, heptane), an organic acid (e.g., acetic acid), mixtures thereof, and aqueous solutions thereof.

20


Step 3



Compound (II)

Monitored by HPLC

- i) THF/H₂O under N₂
- ii) Et₃N
- iii) ClCH₂C(O)Cl
- iv) i-PrOH/H₂O, filter
(95% yield)



The substituted tetrahydro- β -carboline hydrochloride (II) (83.7 kg, 216 mol) was suspended in THF (335 L) and deionized water (84 L), and treated with triethylamine (Et_3N) (57.0 kg, 560 mol) at 0°C to 20°C under an N_2 atmosphere. Chloroacetyl chloride ($\text{ClCH}_2\text{C}(\text{O})\text{Cl}$) (34.2 kg, 300 mol) in dry THF (0.6 volumes) then was added at a rate to maintain the temperature at 0°C to 10°C, followed by stirring the reaction mixture for two hours. The reaction was monitored by HPLC for a Compound (II) content of 4%, by weight, or less. After the acylation reaction was completed, the reaction mixture was subjected to distillation, under vacuum at 30°C to 50°C, to reduce the volume by about 30%. Then, water (84 L) and isopropyl alcohol (335 L) were added, and the reaction mixture was distilled a second time under reduced pressure at 30°C to 50°C to remove about 20% of the volume. The reaction mixture then was cooled to 20°C to 25°C and stirred for two hours. The reaction product crystallized, and was filtered and washed with isopropyl alcohol. The reaction product was dried under vacuum at 80°C to yield 86.7 kg (95%) of chloroacetyl carboline.

- 24 -


cis-1-(1,3-benzodioxol-5-yl)-2,3,4,9-tetrahydro-1*H*-pyrido[3,4-*b*]indole-3-carboxylic acid methyl ester.

¹H NMR (400 MHz DMSO) δ: 10.86 (1H, s), 7.54 (1H, d, J=7.4), 7.27 (1H, d, J=8.0), 7.11-6.99 (2H, m), 6.81-6.75 (2H, m), 6.63 (1H, s), 6.45 (1H, d, J=8.2), 5.97 (2H, d, J=5.8), 5.19 (1H, d, J=6.6), 4.83 (1H, d, J=14), 4.43 (1H, d, J=14), 3.45 (1H, d, J=16), 3.10-3.03 (4H, m).

Alternative solvents for Step 3 include
 10 low molecular weight alcohols, such as isopropyl alcohol or n-propyl alcohol; acetone; and methylene chloride.

Step 4


15



Monitored by HPLC →

- i) THF under N₂
- ii) MeNH₂ (40% aq)
- iii) aqueous HCl
- iv) i-PrOH/H₂O, filter
(95% yield)

- 25 -



Compound (I)

5

The chloroacetyl carboline (86.0 kg, 201 mol) was added to THF (430 L), and the resulting mixture was heated to 30°C to 55°C under an N₂ atmosphere and stirred. The resulting solution then 10 was filtered at a temperature of 45°C to 50°C to remove undissolved particles. Methylamine (78.2 kg, 1000 mol) then was added to the solution at a temperature of 5°C to 25°C. The resulting mixture was stirred at a temperature of 30°C to 55°C for 15 about 1 hour, or until HPLC analysis indicated a complete reaction; i.e., less than 1% of the chloroacetyl carboline remained. The mixture was cooled to 0°C to 30°C, isopropyl alcohol (344 L) and water (175 L) then were added, followed by 12M 20 hydrochloric acid (67 L) to neutralize the excess methylamine, i.e., to pH 2 to 9.4. Upon essentially complete removal of THF by distillation, the solution was treated with isopropyl alcohol (260 L) and water (75 L) and cooled to -5°C to 30°C, followed by 25 stirring for two hours to crystallize the product. The product was filtered and washed with cold (0°C

- 26 -

to 5°C) 50% aqueous isopropyl alcohol. The wash solvent was filtered at -5°C to 30°C, and the product was dried under vacuum at 80°C or less (e.g., 70°C to 80°C) to yield 75 kg (94.6%) of Compound 5 (I). For increased purity, Compound (I) optionally can be recrystallized from acetic acid.

A reference standard was prepared in the same manner, with additional purification by double recrystallization from glacial acetic acid (HOAc). 10 Compound (I) was dissolved in 13 volumes of HOAc at 80°C, and the solution was concentrated to one-third original volume and then cooled to ambient temperature. The product was filtered; washed with MTBE, and dried in vacuum at 80°C. ^1H NMR (400 MHz, DMSO) 15 δ: 11.0 (1H, s), 7.52 (1H, d, J=7.3 Hz), 7.28 (1H, d, 7.9 Hz), 7.28 (1H, d, J=7.9 Hz), 7.06-6.98 (2H, m), 6.85 (1H, s), 6.76 (2H, s), 6.11 (1H, s), 5.91 (2H, s), 4.40-4.35 (1H, dd, J=4.27, 11.6 Hz), 4.17 (1H, d, J=17.1 Hz), 3.93 (1H, d; J=17.1), 3.54-3.47 (1H, dd, J=4.6, 11.3 Hz), 3.32 (1H, s), 3.00-2.91 (4H, m). HPLC Details: Column: Zorbax SB-Phenyl, 4.6 mm i.d. x 25 mm; 2.5 μm particles; Mobile Phase: acetonitrile, 0.1% TFA in water; Flow rate = 1.0 mL/min.; Detector wavelength = 285 nm; Injection 20 volume = 20 μL; Column temperature = ambient; and Retention time = 9.0 min.

Obviously, many modifications and variations of the invention as set forth above can be 30 made without departing from the spirit and scope thereof, and, therefore, only such limitations

- 27 -

should be imposed as are indicated by the appended
claims.